Traumatic Optic Neuropathy Treatment Trial (TONTT)
NCT01783847 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 117
Last updated 2019-05-07
Summary
The pathophysiology of Traumatic Optic Neuropathy (TON) is thought to be multifactorial, and some researchers have also postulated a primary and secondary mechanism of injury.TON is categorized as direct or indirect.In indirect TON cases, the injury to the axons is thought to be induced by shearing forces that are transmitted to the fibers or to the vascular supply of the nerve. Studies have shown that forces applied to the frontal bone and malar eminences are transferred and concentrated in the area near the optic canal. The tight adherence of the optic nerve's dural sheath to the periosteum within the optic canal is also thought to contribute to this segment of the nerve being extremely susceptible to the deformative stresses of the skull bones. Such injury leads to ischemic injury to the axons of the retinal ganglion cells within the optic canal. At present, no studies validate a particular approach to the management of TON. There are three management lines for these patients that include 1)observation only;2)medical treatment with high or megadoses of methylprednisolone; and 3)surgical intervention. Generally no line precedes the others and additionally, medical or surgical interventions may result in serious side effects or complications. In 2005, the results of the Corticosteroid Randomization after Significant Head Injury (CRASH) trial raised concerns regarding the use of mega dose steroids in traumatic brain injury. This study was the largest randomized study that evaluated steroids in patients with traumatic brain injury and was stopped early due to the significantly increased risk of death in patients that received mega dose steroids at their 6-month follow-up when compared with the placebo group (25.7% vs 22.3%; Relative Risk 1.15 Confidence Interval 1.07 to 1.24; p=0.0001). Although the etiology of the increased risk of death was not determined, the findings of this study should be taken into consideration when managing cases of TON with concurrent traumatic brain injury. Very recently it has been shown the cytokine hormone erythropoietin (EPO) that had been long known and used as a valuable agent to promote hematopoiesis has been protective in experimental models of mechanical trauma, neuroinflammation, cerebral and retinal ischemia, and even in a human stroke trial, and most notably in optic nerve transection. A double blind placebo-controlled multicenter trial on EPO add-on treatment in chronic schizophrenic men was performed. Treatment over 12 weeks with high-dose weekly (40,000 IU intravenously) EPO led to significant improvement of cognitive performance compared to placebo controls. Different studies have been performed on the effect of EPO on neuropathy in different studies. The investigators recently published our results on treating patients with TON with EPO and found it safe and effective. Patients were compared with a historical control group of patients who received no treatment for TON. A better visual recovery was found. The aim of this study is to determine the effectiveness of EPO on TON in a Multi- center clinical trial using a semi-experimental design.
Conditions
- Traumatic Optic Neuropathy
Interventions
- DRUG
-
Recombinant human erythropoietin (EPO)
4000 units per vial
- OTHER
-
Observation
Just observation
- DRUG
-
Methyl prednisolone
250 mg every 6 hours for 3 days.
Sponsors & Collaborators
-
Iran University of Medical Sciences
collaborator OTHER -
Mashhad University of Medical Sciences
collaborator OTHER -
Shahid Beheshti University of Medical Sciences
collaborator OTHER -
Tehran University of Medical Sciences
lead OTHER
Principal Investigators
-
Mohsen B Kashkouli, MD · Iran University of Medical Sciences
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 5 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-28
- Primary Completion
- 2016-04-30
- Completion
- 2017-02-28
Countries
- Iran
Study Locations
More Related Trials
-
A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema
NCT00369486 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy
NCT04469777 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Erythropoietin in the Treatment of Scleral Necrosis
NCT05476042 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
NCT02638714 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Ischemic Optic Neuropathy Decompression Trial (IONDT)
NCT00000127 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery
NCT00801450 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases
NCT07341919 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema
NCT00369863 ·Status: COMPLETED ·Phase: PHASE2
-
Topical Insulin for Glaucoma
NCT05206877 ·Status: RECRUITING ·Phase: PHASE1
-
Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema
NCT00900887 ·Status: COMPLETED ·Phase: PHASE2
-
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
NCT07330713 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
NCT00367133 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
NCT04300881 ·Status: TERMINATED ·Phase: PHASE2
-
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
NCT05909488 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa
NCT03944239 ·Status: UNKNOWN ·Phase: PHASE1
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
NCT02374060 ·Status: COMPLETED ·Phase: PHASE3
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
NCT00101764 ·Status: COMPLETED ·Phase: PHASE1
-
PRP vs PRP+IVC for Severe nPDR
NCT03863535 ·Status: UNKNOWN ·Phase: NA
-
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
NCT01607671 ·Status: WITHDRAWN ·Phase: PHASE1
-
Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION
NCT02329288 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
NCT02314299 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema
NCT00148265 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema
NCT02131350 ·Status: COMPLETED ·Phase: PHASE4
-
The Therapeutic Effect of Dysthyroid Optic Neuropathy
NCT04096612 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa
NCT05413148 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3